Live Earnings Conference Call: Humacyte will host a live Q2 2026 earnings call on August 12, 2026 at 8:00AM ET. NASDAQ:HUMA Humacyte Q2 2026 Earnings Report $0.71 -0.03 (-4.63%) Closing price 08/11/2026 04:00 PM EasternExtended Trading$0.64 -0.07 (-9.44%) As of 07:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Live Call not available Upcoming EventEarnings Conference CallHumacyte Q2 202600:00 / 00:00Live Transcript Follow Audio Humacyte EPS ResultsActual EPS-$0.16Consensus EPS -$0.10Beat/MissMissed by -$0.06One Year Ago EPSN/AHumacyte Revenue ResultsActual Revenue$0.41 millionExpected Revenue$1.12 millionBeat/MissMissed by -$713.00 thousandYoY Revenue GrowthN/AHumacyte Announcement DetailsQuarterQ2 2026Date8/12/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Humacyte Earnings HeadlinesHumacyte Announces Second Quarter 2026 Financial Results and Provides Business Update22 minutes ago | globenewswire.comHumacyte Q2 2026 earnings previewAugust 11 at 1:35 PM | msn.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.August 12 at 1:00 AM | Investors Alley (Ad)Humacyte (HUMA) Expected to Post Earnings on WednesdayAugust 11 at 1:26 AM | americanbankingnews.comHumacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMAAugust 10 at 1:00 PM | businesswire.comHumacyte to Report Second Quarter 2026 Financial Results and Host Corporate Update Webcast on August 12August 7, 2026 | quiverquant.comQSee More Humacyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Humacyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Humacyte and other key companies, straight to your email. Email Address About HumacyteHumacyte (NASDAQ:HUMA) is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications. The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation. Humacyte is also exploring additional indications, including peripheral and coronary artery bypass and central venous access, with the goal of addressing significant unmet medical needs in cardiovascular surgery and interventional medicine. Research and development efforts are supported by Good Manufacturing Practice (GMP) facilities in the United States, enabling scale-up from laboratory to commercial production. Founded in 2004 by Dr. Scott B. Rhodes at Duke University, Humacyte is headquartered in Durham, North Carolina, with ongoing clinical programs and partnerships extending into Europe and North America. The company is led by a management team with experience spanning cell therapy, regenerative medicine and vascular surgery. Humacyte continues to work alongside clinical investigators and strategic collaborators to advance its HAV technology toward regulatory approval and broad clinical adoption.View Humacyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Rocket Lab’s Record Quarter Still Left Investors Waiting on NeutronAtlassian Just Pulled Off the Software Comeback Wall Street WantedAST SpaceMobile Earnings Just Reminded Investors How Risky Space Can BeMeta’s Muse Glimmer Release Reframes Its AI Spending BetNVIDIA’s Rally Sets Up a Bigger Test Ahead of EarningsCaterpillar’s Blowout Quarter May Point to More Industrial WinnersOklo’s Revenue Transition Gives Bulls a New Reason to Watch Upcoming Earnings Brookfield (8/13/2026)NU (8/13/2026)Applied Materials (8/13/2026)BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
